Grant A McArthur

Grant A McArthur

UNVERIFIED PROFILE

Are you Grant A McArthur?   Register this Author

Register author
Grant A McArthur

Grant A McArthur

Publications by authors named "Grant A McArthur"

Are you Grant A McArthur?   Register this Author

100Publications

7826Reads

13Profile Views

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in -Mutant Melanoma.

Clin Cancer Res 2020 Jan 15;26(1):46-53. Epub 2019 Nov 15.

Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia, and University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-4180DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942621PMC
January 2020

High-resolution MRI demonstrates that more than ninety percent of small intracranial melanoma metastases develop in close relationship to the leptomeninges.

Neuro Oncol 2019 Sep 9. Epub 2019 Sep 9.

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz171DOI Listing
September 2019

Lymphatic and Hematogenous Dissemination in Patients With Primary Cutaneous Melanoma.

JAMA Dermatol 2019 Sep 11. Epub 2019 Sep 11.

School of Public Health and Preventive Medicine, Monash University, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2019.2658DOI Listing
September 2019

A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response.

J Invest Dermatol 2019 Sep 30. Epub 2019 Sep 30.

Victorian Melanoma Service, Alfred Hospital, Melbourne, Victoria, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2019.07.725DOI Listing
September 2019

Molecular Genomic Profiling of Melanocytic Nevi.

J Invest Dermatol 2019 Aug 14;139(8):1762-1768. Epub 2019 Feb 14.

Melanoma Institute Australia, The University of Sydney, New South Wales, Australia; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0022202X193011
Publisher Site
http://dx.doi.org/10.1016/j.jid.2018.12.033DOI Listing
August 2019

Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel.

J Mol Diagn 2019 May 5;21(3):418-426. Epub 2019 Feb 5.

Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15251578183023
Publisher Site
http://dx.doi.org/10.1016/j.jmoldx.2018.12.001DOI Listing
May 2019

Concordance of somatic mutational profile in multiple primary melanomas.

Pigment Cell Melanoma Res 2018 09 15;31(5):592-603. Epub 2018 Apr 15.

Victorian Melanoma Service, Alfred Hospital, Melbourne, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12702DOI Listing
September 2018

A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.

Cancer Chemother Pharmacol 2018 09 9;82(3):493-503. Epub 2018 Jul 9.

The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3634-4DOI Listing
September 2018

Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation - Authors' reply.

Lancet Oncol 2018 08;19(8):e367

Disciplines of Medical Oncology, Melanoma Institute Australia, University of Sydney, Sydney, NSW 2065, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30508-4DOI Listing
August 2018

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Lancet Oncol 2018 05 27;19(5):672-681. Epub 2018 Mar 27.

Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia; Medical, Dental and Health Sciences, University of Melbourne, Parkville, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30139-6DOI Listing
May 2018

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.

Br J Cancer 2018 05 14;118(10):1289-1295. Epub 2018 May 14.

Victorian Melanoma Service, Alfred Hospital, Melbourne, VIC, 3004, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0088-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959932PMC
May 2018

Optimizing Amplification of the GC-Rich Promoter Region Using 7-Deaza-dGTP for Droplet Digital PCR Quantification of Promoter Mutations.

Clin Chem 2018 04 30;64(4):745-747. Epub 2018 Jan 30.

Department of Pathology, University of Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2017.284257DOI Listing
April 2018

Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.

Br J Cancer 2017 Sep 8;117(7):1026-1035. Epub 2017 Aug 8.

Victorian Melanoma Service, Alfred Hospital, Melbourne, Victoria 3004, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.254DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625668PMC
September 2017

The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.

Eur J Nucl Med Mol Imaging 2017 Aug 7;44(Suppl 1):67-77. Epub 2017 Apr 7.

The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-017-3691-7DOI Listing
August 2017

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?

J Transl Med 2017 08 8;15(1):173. Epub 2017 Aug 8.

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-017-1278-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549368PMC
August 2017

Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.

Int J Cancer 2016 Jul 10;139(1):194-204. Epub 2016 Mar 10.

Peter MacCallum Cancer Centre, Translational Research Laboratory, East Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.30056DOI Listing
July 2016

Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma.

Pharmacol Res 2016 05 26;107:42-47. Epub 2016 Feb 26.

Molecular Oncology Laboratory, Oncogenic Signaling and Growth Control Program, Peter MacCallum Cancer Centre, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Translational Research Laboratory, Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Australia; Department of Pathology, University of Melbourne, Australia; Department of Medicine, St. Vincent's Hospital, University of Melbourne, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2016.02.009DOI Listing
May 2016

Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.

J Clin Oncol 2016 Apr 13;34(12):e104-6. Epub 2014 Oct 13.

Peter MacCallum Cancer Centre, East Melbourne; University of Melbourne, Parkville, Victoria

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/10/10/JCO.2013.51
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.51.3572
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.51.3572DOI Listing
April 2016

BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.

J Natl Compr Canc Netw 2016 03 8;14(3):249-54. Epub 2016 Mar 8.

Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0030DOI Listing
March 2016

Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.

Cancer Discov 2016 Jan 21;6(1):59-70. Epub 2015 Oct 21.

Division of Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia. Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria, Australia. Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-0673DOI Listing
January 2016

Survival of patients with advanced metastatic melanoma: The impact of novel therapies.

Eur J Cancer 2016 Jan 17;53:125-34. Epub 2015 Dec 17.

Center for Dermatooncology, Department of Dermatology, University Tuebingen, 72074 Tuebingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.09.013DOI Listing
January 2016

CDK4 inhibitors an emerging strategy for the treatment of melanoma.

Melanoma Manag 2015 Aug 10;2(3):255-266. Epub 2015 Aug 10.

Department of Cancer Medicine, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.15.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094902PMC
August 2015

Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet.

Authors:
Grant A McArthur

Front Oncol 2015 17;5:161. Epub 2015 Jul 17.

Department of Cancer Medicine, Peter MacCallum Cancer Centre , East Melbourne, VIC , Australia ; Department of Pathology, University of Melbourne , Parkville, VIC , Australia ; Department of Medicine, St Vincent's Hospital, University of Melbourne , Fitzroy, VIC , Australia ; Sir Peter MacCallum Department of Oncology, University of Melbourne , East Melbourne, VIC , Australia ; Molecular Oncology Laboratory, Oncogenic Signaling and Growth Control Program, Peter MacCallum Cancer Centre , East Melbourne, VIC , Australia ; Translational Research Laboratory, Cancer Therapeutics Program, Peter MacCallum Cancer Centre , East Melbourne, VIC , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2015.00161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505146PMC
August 2015

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Sci Signal 2015 Aug 18;8(390):ra82. Epub 2015 Aug 18.

Molecular Oncology Laboratory, Peter MacCallum Cancer Centre, St. Andrew's Place, East Melbourne, Victoria 3002, Australia. Oncogenic Signalling and Growth Control Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia. Sir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria 3010, Australia. Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia. Department of Pathology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria 3010, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scisignal.aab1111DOI Listing
August 2015

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

N Engl J Med 2015 Jul 31;373(1):23-34. Epub 2015 May 31.

From the Department of Medical Oncology, Royal Marsden Hospital, London (J.L.), and South West Wales Cancer Institute, Singleton Hospital, Swansea (J.W.) - both in the United Kingdom; Melanoma Oncology Unit, Veneto Region Oncology Research Institute, Padua (V.C.-S.), Oncology of Melanoma Unit, European Institute of Oncology, Milan (P.F.F.), University Hospital of Siena, Siena (M.M.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; Division of Medical Oncology, University of Colorado, Denver, Denver (R.G.); Aix-Marseille University, Hôpital de La Timone, Assitance Publique-Hôpitaux de Marseille, Marseille (J.J.G.), and Hôtel Dieu Place Alexis Ricordeau, Nantes (B.D.) - both in France; Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); Departments of Internal Medicine and Dermatology, University of Michigan, Ann Arbor (C.D.L.); Department of Dermatology, University of Essen, Essen, Germany (D.S.); University of Zürich Hospital, Zurich, Switzerland (R.D.); Cross Cancer Institute, Edmonton, AB, Canada (M. Smylie); Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland (P.R.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), and Westmead and Blacktown Hospitals (M.S.C.) and Melanoma Institute Australia (M.S.C., G.V.L.), University of Sydney, and the Mater Hospital (G.V.L.), Sydney, and Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC (G.A.M.) - all in Australia; Division of Medical Oncology, the Netherlands Cancer Institute, Amsterdam (J.B.H.); Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid (I.M.-R.); Ludwig Center, Memorial Sloan Kettering Cancer Center (M.K.C., M.A.P., J.D.W.) and Weill Cornell Medical College (M.K.C., M.A.P., J.D.W.) - both in New York; Huntsman Cancer Institute, University of Utah, Salt Lake City (K.G.); Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital, Yale University Sc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1504030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698905PMC
July 2015

Adjuvant immunotherapy for cancer: the next step.

Lancet Oncol 2015 May 31;16(5):478-80. Epub 2015 Mar 31.

Divisions of Cancer Medicine and Research, Peter MacCallum Cancer Centre, University of Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S147020451570162
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(15)70162-2DOI Listing
May 2015

Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly.

FASEB J 2015 Apr 30;29(4):1426-34. Epub 2014 Dec 30.

*Surgical Oncology Research Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia; University of Melbourne Department of Medicine, Austin Health, Heidelberg, Victoria, Australia; Translational Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; St. Vincent's Institute of Medical Research and University of Melbourne Department of Medicine, St. Vincent's Hospital, Fitzroy, Victoria, Australia; Bone Research Program, ANZAC Research Institute, The University of Sydney, Sydney, New South Wales, Australia; Differentiation and Transcription Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; **Department of Pathology, University of Melbourne, Parkville, Victoria, Australia; Molecular Oncology Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; and University of Melbourne Department of Surgery, St. Vincent's Hospital, Fitzroy, Victoria, Australia

View Article

Download full-text PDF

Source
http://www.fasebj.org/content/29/4/1426.full.pdf
Web Search
http://www.fasebj.org/cgi/doi/10.1096/fj.14-262782
Publisher Site
http://dx.doi.org/10.1096/fj.14-262782DOI Listing
April 2015

Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.

Cancer Immunol Immunother 2015 Apr 7;64(4):507-18. Epub 2015 Feb 7.

Ludwig Institute for Cancer Research (Melbourne-Austin Branch), 147-163 Studley Road, Heidelberg, VIC, 3084, Australia,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-015-1656-xDOI Listing
April 2015

Radiotherapy complements immune checkpoint blockade.

Cancer Cell 2015 Apr;27(4):437-8

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia; School of Medicine, University of Queensland, Herston, QLD 4006, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2015.03.015DOI Listing
April 2015

Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma.

Oncotarget 2015 Jan;6(2):1115-27

Division of Cancer Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359221PMC
http://dx.doi.org/10.18632/oncotarget.2747DOI Listing
January 2015

The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.

J Invest Dermatol 2014 Nov 6;134(11):2795-2805. Epub 2014 Jun 6.

Melanoma Research Group, Kolling Institute of Medical Research, University of Sydney, St Leonards, New South Wales, Australia; Melanoma Institute of Australia, North Sydney, New South Wales, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0022202X153655
Publisher Site
http://dx.doi.org/10.1038/jid.2014.243DOI Listing
November 2014

Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151.

Pigment Cell Melanoma Res 2014 Nov 3;27(6):1126-37. Epub 2014 Jul 3.

Melanoma Research Group, Kolling Institute of Medical Research, University of Sydney, St Leonards, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12282DOI Listing
November 2014

Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.

Pigment Cell Melanoma Res 2014 Nov 4;27(6):1117-25. Epub 2014 Aug 4.

Victorian Melanoma Service, Alfred Hospital, Melbourne, Vic., Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic., Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12295DOI Listing
November 2014

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

N Engl J Med 2014 Nov 29;371(20):1867-76. Epub 2014 Sep 29.

From Royal Marsden Hospital, London (J.L.); Istituto Nazionale Tumori Fondazione G. Pascale, Naples (P.A.A.), Azienda Ospedaliera Universitaria Senese, Siena (M. Maio), and Papa Giovanni XXIII Hospital, Bergamo (M. Mandalà) - all in Italy; Hôtel Dieu Place Alexis Ricordeau, Nantes (B.D.), Centre Hospitalier Lyon Sud, Pierre-Bénite (L.T.), and Hôpital Saint André, Bordeaux (C.D.) - all in France; Princess Alexandra Hospital, Woolloongabba, QLD (V.A.), and Peter MacCallum Cancer Centre, Melbourne, VIC (G.A.M.) - both in Australia; National Institute of Oncology, Budapest, Hungary (G.L.); N.N. Blokhin Russian Cancer Research Center, Moscow (L.D.), and Moscow City Oncology Hospital 62, Krasnogorsk (D.S.) - both in Russia; Hospital Universitario Virgen Macarena, Seville, Spain (L.C.-M.); University of Tübingen, Tübingen, Germany (C.G.); Genentech, South San Francisco, CA (M.A.S., I.C., N.C., S.P.H.); and Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, Los Angeles (A.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1408868DOI Listing
November 2014

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.

Melanoma Res 2014 Oct;24(5):504-8

aDepartment of Medical Oncology, Cancer Centre, Sir Charles Gairdner Hospital bSchool of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia cPeter MacCallum Cancer Centre, East Melbourne dSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria eMelanoma Institute Australia, North Sydney fUniversity of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000099DOI Listing
October 2014

Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.

Am J Ophthalmol 2014 Oct 15;158(4):831-837.e2. Epub 2014 Jul 15.

Department of Medicine, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajo.2014.07.003DOI Listing
October 2014

The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound.

Cell Rep 2014 May 9;7(4):1009-19. Epub 2014 May 9.

Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3002, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3002, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2014.04.008DOI Listing
May 2014

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.

Cancer Discov 2014 Apr 27;4(4):423-33. Epub 2014 Jan 27.

1Molecular Oncology Laboratory, Oncogenic Signaling and Growth Control Program, 2Translational Research Laboratory, Cancer Therapeutics Program, 3Bioinformatics Core Facility, 4The Cancer Signalling Laboratory, Oncogenic Signaling and Growth Control Program, 5Gene Regulation Laboratory, Cancer Therapeutics Program, 6Molecular Imaging and Targeted Therapeutics Laboratory, Cancer Therapeutics Program, 7Department of Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne; 8Sir Peter MacCallum Department of Oncology, Departments of 9Biochemistry and Molecular Biology, and 10Pathology, University of Melbourne, Parkville; 11Metabolic Remodelling Laboratory, Metabolic Research Unit, School of Medicine, Deakin University, Waurn Ponds; 12Department of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, Victoria; 13Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead; 14Department of Tissue Pathology & Diagnostic Oncology, Royal Prince Alfred Hospital; 15Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; 16Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; and 17Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0440DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110245PMC
April 2014

Targeting the nucleolus for cancer-specific activation of p53.

Drug Discov Today 2014 Mar 28;19(3):259-65. Epub 2013 Aug 28.

The Translational Genomics Research Institute, 445 N. Fifth Street, Phoenix, AZ 85004, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2013.08.012DOI Listing
March 2014

Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.

Nucl Med Biol 2014 Feb 15;41(2):148-54. Epub 2013 Nov 15.

Division of Cancer Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Centre for Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Department of Medicine, St Vincent's Hospital, The University of Melbourne, Parkville, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nucmedbio.2013.11.001DOI Listing
February 2014

Co-targeting deoxyribonucleic acid-dependent protein kinase and poly(adenosine diphosphate-ribose) polymerase-1 promotes accelerated senescence of irradiated cancer cells.

Int J Radiat Oncol Biol Phys 2014 Feb;88(2):385-94

Division of Cancer Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Department of Medicine, St. Vincent's Hospital, University of Melbourne, Parkville, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://file2.selleckchem.com/citations/Pi-thrin-alpha-AG0146
Web Search
http://dx.doi.org/10.1016/j.ijrobp.2013.10.043DOI Listing
February 2014

Navigating the challenge of tumor heterogeneity in cancer therapy.

Cancer Discov 2014 Feb;4(2):146-8

1Cancer Therapeutics Program, Division of Cancer Research, Peter MacCallum Cancer Centre, East Melbourne; 2Sir Peter MacCallum Department of Oncology and 3Department of Pathology, University of Melbourne, Parkville; and 4Department of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-1042DOI Listing
February 2014

Adjuvant interferon in melanoma: is duration of therapy important?

Authors:
Grant A McArthur

J Clin Oncol 2014 Jan 16;32(3):171-3. Epub 2013 Dec 16.

Peter MacCallum Cancer Centre, East Melbourne; University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.5179DOI Listing
January 2014

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.

Eur J Cancer 2013 Dec 3;49(18):3936-44. Epub 2013 Sep 3.

Oncogenic Signalling and Growth Control Program, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Melbourne, Victoria 8006, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3010, Australia; Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria 3010, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.08.007DOI Listing
December 2013

Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours.

Sci Rep 2013 Dec 13;3:3494. Epub 2013 Dec 13.

1] Molecular Pathology Research and Development Laboratory, Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, 3002, Australia [2] Department of Pathology, The University of Melbourne, Parkville, Victoria, 3010, Australia [3] Translational Genomics and Epigenomics Laboratory, Ludwig Institute for Cancer Research, The Olivia Newton-John Cancer and Wellness Centre, Heidelberg, Victoria, 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep03494DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861801PMC
December 2013

AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.

FEBS J 2013 Nov 13;280(21):5307-16. Epub 2013 Feb 13.

Division of Research, Peter MacCallum Cancer Centre, East Melbourne, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/febs.12135DOI Listing
November 2013

The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.

Clin Cancer Res 2013 Oct;19(19):5320-8

Authors' Affiliations: Sir Peter MacCallum Department of Oncology and Departments of Pathology and Biochemistry and Molecular Biology, University of Melbourne, Parkville; Department of Medicine, St. Vincent's Hospital, University of Melbourne, Fitzroy; Molecular Oncology Laboratory, Oncogenic Signaling and Growth Control Program; Translational Research Laboratory, Cancer Therapeutics Program; and Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0259DOI Listing
October 2013

Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma.

Histopathology 2013 Sep 26;63(3):351-61. Epub 2013 Jun 26.

Product Development-Oncology, Genentech Inc., South San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12169DOI Listing
September 2013

BRAF-targeted therapy and immune responses to melanoma.

Oncoimmunology 2013 Jun 9;2(6):e24462. Epub 2013 May 9.

Immunology in Cancer and Infection Laboratory; Queensland Institute of Medical Research; Herston, QLD Australia ; Department of Pathology; University of Melbourne; Parkville, VIC Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.24462DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716742PMC
June 2013

Dysregulation of the basal RNA polymerase transcription apparatus in cancer.

Nat Rev Cancer 2013 May;13(5):299-314

Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne 8006, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc3496DOI Listing
May 2013

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

J Clin Invest 2013 Mar 1;123(3):1371-81. Epub 2013 Feb 1.

Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI66236DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582139PMC
March 2013